Grant Giver Name
MENA TAVI is a single arm, prospective, open label and multicenter registry. The objective is to evaluate the ACURATE NEO 2 in the Middle East population suffering from severe symptomatic aortic stenosis. The objective is to enroll 100 patients from 6 investigational sites and patients will be followed up to 30 days after procedure.
The primary endpoint is the combined endpoint at discharge of
- All cause mortality or
- Any stroke (disabling and non-disabling)
Around 3 countries across Saudi Arabia, Egypt and Lebanon.
Number of investigational sites: 6